1,739 Shares in IQVIA Holdings Inc. $IQV Bought by DRW Securities LLC

Key Points

• DRW Securities LLC has acquired a new position in IQVIA Holdings Inc., purchasing 1,739 shares valued at approximately $307,000.
• Several hedge funds have increased their stakes in IQVIA, with most institutional investors now holding 89.62% of the company's stock.
• IQVIA's shares have a 12-month price range between $134.65 and $252.88, and it reported a 5.3% year-over-year revenue increase during its latest earnings report.

DRW Securities LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,739 shares of the medical research company's stock, valued at approximately $307,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Pacer Advisors Inc. raised its stake in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after acquiring an additional 854,732 shares during the period. JPMorgan Chase & Co. raised its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in IQVIA by 211.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after buying an additional 655,153 shares in the last quarter. Nuveen LLC purchased a new position in IQVIA during the 1st quarter valued at about $76,328,000. Finally, Cadian Capital Management LP purchased a new position in IQVIA during the 4th quarter valued at about $78,604,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Evercore ISI lifted their target price on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $229.86.

IQVIA Price Performance

Shares of NYSE IQV traded up $3.67 during midday trading on Friday, hitting $187.75. 1,263,215 shares of the company's stock were exchanged, compared to its average volume of 1,128,696. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $249.43. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $31.92 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.02 and a beta of 1.32. The business's fifty day moving average price is $179.88 and its two-hundred day moving average price is $167.61.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.